This page gives an overview of some of the diabetes-related stories we have seen in the news this month. We especially look out for a newsworthy story focussing on medtech and sensor technology.
💛💛💛
Edinburgh Zoo have reported that Nala, one of their Giant Anteaters, has been fitted with a Dexcom to monitor glucose levels following a type1 diagnosis.
Diabetes Week is an annual event in the UK to raising awareness of diabetes and fundraise for research into the condition. There are lots of events to participate in. For more details take a look at the following:
https://www.diabetes.org.uk/diabetes-week
💛💛💛
3 June 2022
Abbott have announced that they are designing a first-of-its-kind biowearable that will enable people with diabetes to continuously monitor glucose and ketones in one sensor.
The glucose-ketone sensor will be the same size as Abbott’s FreeStyle Libre 3 sensor, recently cleared by the FDA for use in the USA.
It will connect to Abbott’s digital ecosystem that includes personal and caregiver mobile apps along with cloud-based data management software for remote monitoring by healthcare professionals.
Jared Watkin, senior vice president of Abbott’s diabetes care business, said:
“We’re designing our glucose-ketone monitoring system with superior sensing technology that will pair with industry-leading insulin pumps to create a best-in-class solution. We’re optimistic that this will be the next big advancement in diabetes tech and a breakthrough for people with diabetes, especially those who are at risk of developing diabetic ketoacidosis.”
See press release here: https://abbott.mediaroom.com/2022-06-03-Abbott-Announces-Development-of-Novel-Continuous-Glucose-Ketone-Monitoring-System
💛💛💛
June 2022
Following recent rumours in the medtech industry, Dexcom have declared that they are not currently in acquisition talks with Insulet.
💛💛💛
June 2022
The latest data from the NHS shows that nearly 75% of T1Ds have access to 'flash' ie. FreeStyle Libre, or CGM.
98% of pregnant T1Ds have access to 'flash' or CGM.
All T1Ds have access to online education ie. Digibete, Dafne or similar.
Work on closed loops has been continuing and it's expected they'll be some big announcements about widening availability of this through the NHS soon...
💛💛💛
June 2022
Following FDA clearance for the Libre 3 at the end of May, Abbott are looking to maintain its momentum and hold off competition from Dexcom.
They have presented data on the mean absolute relative difference (MARD) of the Libre 3 showing an overall MARD of 7.9%, leading Abbott to claim it is the first device of its kind to post a sub-8% result.
Libre 2 had a MARD of 9.3%, compared to 8.7% for Dexcom’s rival G7 CGM device.
💛💛💛
7 June 2022
Dexcom are eagerly (as the diabetes community is too) awaiting a decision from the Food and Drug Administration (FDA) for clearance of the G7. However, their CEO, Kevin Sayer, recently confirmed that there is more work to be done and they currently do not have a timeline.
With regard to the UK launch of the G7, he said "We’ll get to a full launch in the U.K. shortly and it’ll be our first major market in Europe.
He went on to say that the rollout will continue "to some of the other large geographies where CGM coverage is really strong over the course of the rest of the year."
💛💛💛
Read May News: Click here.
Read April News: Click here.
Read March News: Click here.
Read February News: Click here.
Read January News: Click here.
